Freeline Therapeutics shares are trading higher after the company released initial data from first cohort of Phase 1/2 GALILEO-1 trial of FLT201 gene therapy for Gaucher disease.
Portfolio Pulse from Benzinga Newsdesk
Freeline Therapeutics has released initial data from the first cohort of its Phase 1/2 GALILEO-1 trial of FLT201 gene therapy for Gaucher disease. The positive results have led to an increase in the company's share price.
October 04, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Freeline Therapeutics' positive initial data from its Phase 1/2 GALILEO-1 trial of FLT201 gene therapy for Gaucher disease has led to a rise in its share price.
The positive initial data from Freeline Therapeutics' Phase 1/2 GALILEO-1 trial of FLT201 gene therapy for Gaucher disease indicates a successful progression of the company's product. This positive news is likely to increase investor confidence, leading to a rise in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100